Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate Cancer

Trial Profile

Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2016

At a glance

  • Drugs IMF 001 (Primary) ; MIS 416 (Primary)
  • Indications Prostate cancer; Urogenital cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association
    • 14 Mar 2016 Status changed from active, no longer recruiting to completed.
    • 14 Sep 2015 Status changed from recruiting to Active, no longer recruiting as per University Hospital Medical Information Network - Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top